Additional Risk Minimisation Measures
Pharmaceutical products with marketing authorisation in Centres Spécialités Pharmaceutiques with Additional Risk Minimisation Measures on national territory.

The so-called ‘routine’ risk minimisation measures provide a framework for the Safe Use of medicines. These include :
- Information in the Summary of Product Characteristics (SmPC) for professionals and the patient information leaflet
- Pharmaceutical product primary and secondary packaging
- The introduction of prescribing and dispensing conditions
Where these appear insufficient to ensure safe and effective use, additional risk minimisation measures (aRMMs) may be implemented.
The following pharmaceutical products are subject to additional risk minimisation measures. Centre Spécialités Pharmaceutiques (CSP) advises patients and/or their relatives to consult their healthcare professional if they have not been given the appropriate tools or documents.